Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over Study of Sabatolimab in Patients From Prior Novartis-sponsored Studies
NCT05201066Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2023
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of sabatolimab in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Novartis. Started Feb 2023; status: active, not recruiting.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05201066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201066.